Data presented from controlled studies included 1357 patients, 766 who received Aranesp and 591 patients who received r-HuEPO.
Kontrollitud uuringute andmed hõlmasid 1357 patsienti, kellest 766 raviti Aranesp’ iga ja 591 r- HuEPO- ga.